



CEO purchases shares in Acarix

Acarix, a leader in AI-driven and acoustics-based cardiac diagnostics, has announced that its President and CEO, Aamir Mahmood, has increased his investment in the company.

On February 13, Mahmood acquired 2,300,257 shares at an average price of SEK 0.22, further strengthening his personal stake in Acarix. After the acquisition, the total number of shares held is 7,704,824 and 50,000,000 stock options.

"I am very optimistic about Acarix's future," said Mahmood. "This investment reflects my confidence in our strategy and our ability to generate long-term value for shareholders. I look forward to working with our team to drive continued growth and innovation."

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact

Ashley Wilson, phone +1405 413 5201, email awilson@saxum.com

Attachments

[CEO purchases shares in Acarix](#)